Tether makes a strategic investment of $150 million in smart sleep technology company Eight Sleep
Foresight News reports that Tether Investments has announced a strategic investment in the smart sleep technology company Eight Sleep at a valuation of 1.5 billions USD. Eight Sleep utilizes advanced artificial intelligence and embedded sensors to provide personalized sleep insights and enhancement services. This investment aims to strengthen Eight Sleep's capabilities and establish a long-term partnership to jointly develop advanced AI-driven health technology based on Tether's QVAC architecture.
This investment follows Tether's launch of the QVAC Health personal health platform, which is designed to integrate fragmented health data and ensure users' personal control. QVAC Health allows users to process data directly on their local devices, offering a highly personalized experience.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Intel Confirms Advancement of Musk's "Terafab" Chip Plan Amid Stock Price Pressure
Intel CEO Pat Gelsinger stated that the company will continue to participate in Elon Musk's Terafab project. Previously, Musk revealed ongoing discussions with TSMC about potential collaboration, which raised market concerns over Intel's position in the project. As a result, Intel's stock price once dropped by 3.9%.
Gold Price Forecast: XAU/USD retraces gains and nears two-month lows at $4,104
BUZZ-Caribou shares plunge as company explores sale and cancels cancer project
October 7 - ** Caribou Biosciences (CRBU.O) shares fell 35.9% in pre-market trading to $0.72 ** Caribou Biosciences announced late Tuesday that it is exploring strategic options, including a potential sale, merger, or other transactions, to maximize shareholder value ** Caribou said it plans to halt development of its allogeneic CAR-T cell therapy programs, including vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma ** Caribou also stated it will lay off employees and cut costs, with most layoffs expected to be completed by Q4 2026 ** As of June 30, the company held $113.8 millions in cash, cash equivalents, and marketable securities ** As of the previous trading day's close, the company's share price had dropped about 28% year-to-date (Note: For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them only for reader convenience. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation features.)
Crypto prices
More
